ONC 113 B

Drug Profile

ONC 113 B

Alternative Names: ONC 1-13B; ONC-10013B

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator AllaChem
  • Developer AllaChem; Avionco
  • Class Antiandrogens; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Breast cancer

Most Recent Events

  • 03 Apr 2017 Chemical structure information added
  • 01 Apr 2017 Avionco completes a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Hormone-refractory) in Russia (PO) (NCT03074032)
  • 15 Mar 2017 Adverse events data from a preclinical trial in Prostate cancer and Breast cancer released by AllaChem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top